Advanced search    

Search: authors:"Borja G Cosio"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

The dose of inhaled corticosteroids in patients with COPD: when less is better

advisory board fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Chiesi, Glaxo Smith Kline, Menarini, Novartis, Pfizer, Sandoz, and Teva. Borja G. Cosio reports speaker fees, travel grants, and advisory

Asthma-COPD overlap is not a homogeneous disorder: further supporting data

Asthma-COPD ovelap (ACO) is an umbrella term that encompasses patients with COPD and eosinophilic inflammation (e-COPD) and smoking asthmatics with non-fully reversible airflow obstruction (SA). We compared the clinical characteristics and the inflammatory profile of e-COPD and SA. Patients classified as e-COPD were older and more often male and showed significantly impaired...

The EASI model: A first integrative computational approximation to the natural history of COPD

conflict of interest with the content of this article. Author Contributions Conceptualization: Alvar AgustÂõ, Albert Compte, Rosa Faner, Judith Garcia-Aymerich, Guillaume Noell, Borja G. Cosio, Robert ... AgustÂõ, Albert Compte, Judith Garcia-Aymerich, Josep Maria Anto. Investigation: Alvar AgustÂõ, Albert Compte, Guillaume Noell, Borja G. Cosio, Robert Rodriguez-Roisin. Methodology: Alvar AgustÂõ, Albert

Comorbidity in chronic obstructive pulmonary disease. Related to disease severity?

Comorbidity in chronic obstructive pulmonary disease. Related to disease severity? Jose M Echave-Sustaeta,1 Lorena Comeche Casanova,1 Borja G Cosio,2 Juan Jose Soler-Cataluña,3 Ricardo Garcia-Lujan,1 ... e s e a r C h lorena Comeche Casanova 1 Borja g Cosio 2 Juan Jose soler-Cataluña 3 ricardo garcia-lujan 1 Xavier ribera 4 Background and objective: Several diseases commonly co-exist with chronic

Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort

Rationale The Spanish guideline for COPD (GesEPOC) recommends COPD treatment according to four clinical phenotypes: non-exacerbator phenotype with either chronic bronchitis or emphysema (NE), asthma-COPD overlap syndrome (ACOS), frequent exacerbator phenotype with emphysema (FEE) or frequent exacerbator phenotype with chronic bronchitis (FECB). However, little is known on the...

What pulmonologists think about the asthma–COPD overlap syndrome

Juan P de-Torres,9 Luis M Entrenas,10 Cristóbal Esteban,11 Patricia García-Sidro,12 Borja G Cosio,13 Arturo Huerta,14 Milagros Iriberri,15 José Luis Izquierdo,16 Antolín López-Viña,17 José Luis López ... , Novartis, Pfizer, Rovi, Takeda-Nycomed, and Teva. Borja G Cosio has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer